Table 2. HPV Prevalence in Prostate Cancer Cases by DNA Source and PCR Primers used for HPV DND Detection.
| No. of Studies | No. of Cases | HPV Prevalence (%) (95% CIa) | OR(95% CIa) | |
|---|---|---|---|---|
| HPV DNA specimen | ||||
| Fixed tissue | 17 | 802 | 16.71 (14.18–19.47) | 1.00 |
| Fresh tissue | 16 | 537 | 17.13 (14.04–20.59) | 1.03 (0.76–1.39) |
| Mixed or unclear | 4 | 258 | 19.38 (14.74–24.74) | 1.20 (0.82–1.74) |
| Detection method | ||||
| PCR-based | 32 | 1541 | 17.72 (15.84–19.72) | |
| Broad spectrum primers | 19 | 967 | 12.62 (10.59–14.88) | 1.00 |
| Type-specific primers | 8 | 289 | 27.34 (22.28–32.86) | 2.61 (1.86–3.63) |
| Combination of broad spectrum and type-specific primers | 5 | 285 | 25.26 (20.32–30.73) | 2.34 (1.66–3.29) |
| Non-PCR-basedb | 3 | 56 | 5.36 (1.12–14.87) | |
a95% CI: 95% Confidence interval.
bNon-PCR-based: In situ hybridization, Immunohistochemistry and HC2.